version April 14, 2008

HOVON 68 CLL – CASE REPORT FORMS


 

Pełna wersja do pobrania w pliku PDF:
Ho68 CRF 14042008

A randomized phase III study in previously untreated patients with biological high-risk CLL:

Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab